RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

MarketFest, Yes, this action can really wear down an investor. I remember the post-Shire sub dollar days though, and that was worse. Cortex was still slogging along with CX-516, and the company's continued existence was in doubt - cash levels had dropped to around half a million. So I guess it's all relative.

There's still a decent chance that CX-717 can ultimately be partnered for AD/Neurodegenerative, so the stock's decline at this point looks overdone. There may still be some tax selling to go in December, but if we get closer to a buck, it'll be very tough not to pick up at least a few shares.

The previous financings went through at $1.50 (2003), $2.75 (2004), and $2.66 (2004), so unfortunately this upcoming one could set a new low. I must admit I never expected to see the stock this low again, but such is life in bioland I guess. If there's one thing I've learned in bio investing over the years (the hard way) it's that diversification is not only desirable, it's essential. Dollar cost averaging isn't a bad idea either.